UAE MOHAP approves Spesolimab for GPP flares

The UAE Ministry of Health and Prevention (MOHAP) has approved the first and only therapy by Boehringer Ingelheim for the treatment of adult generalised pustular psoriasis (GPP) flares. 

Spesolimab, the first treatment of its kind in the UAE by Boehringer Ingelheim is the only FDA and EMA-approved medication used to treat GPP flares in adult patients and works to help block a source of inflammation that may cause GPP flares.  

Boehringer Ingelheim, one of the world’s leading research-driven biopharmaceutical companies,…